Transgene SA (EPA: TNG)

Market Cap	92.66M
Revenue (ttm)	6.49M
Net Income (ttm)	-22.91M
Shares Out	131.99M
EPS (ttm)	-0.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,395
Open	0.708
Previous Close	0.702
Day's Range	0.700 - 0.708
52-Week Range	0.700 - 1.520
Beta	0.73
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 7, 2024

About Transgene

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1979
• Employees: 141
• Stock Exchange: Euronext Paris
• Ticker Symbol: TNG

Financial Performance

In 2023, Transgene's revenue was 7.90 million, a decrease of -23.63% compared to the previous year's 10.34 million. Losses were -22.33 million, -31.94% less than in 2022.